Dashboard
1
With a fall in Net Sales of -15.24%, the company declared Very Negative results in Jun 25
- The company has declared negative results in Mar 25 after 8 consecutive negative quarters
- INTEREST(HY) At SEK 51.04 MM has Grown at 6,435.72%
- PRE-TAX PROFIT(Q) At SEK -3.65 MM has Fallen at -111.18%
- NET PROFIT(Q) At SEK 1.27 MM has Fallen at -95.34%
2
With ROE of 6.44%, it has a expensive valuation with a 2.42 Price to Book Value
3
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
SEK 5,242 Million (Small Cap)
38.00
NA
0.00%
-0.13
2.30%
2.50
Revenue and Profits:
Net Sales:
178 Million
(Quarterly Results - Jun 2025)
Net Profit:
2 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
958.58%
0%
958.58%
6 Months
1679.37%
0%
1679.37%
1 Year
946.2%
0%
946.2%
2 Years
1153.68%
0%
1153.68%
3 Years
1605.43%
0%
1605.43%
4 Years
2161.69%
0%
2161.69%
5 Years
2845.34%
0%
2845.34%
Xvivo Perfusion AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
34.92%
EBIT Growth (5y)
58.04%
EBIT to Interest (avg)
3.87
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.15
Sales to Capital Employed (avg)
0.35
Tax Ratio
12.12%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
1.93%
ROE (avg)
3.50%
Valuation key factors
Factor
Value
P/E Ratio
38
Industry P/E
Price to Book Value
2.42
EV to EBIT
47.37
EV to EBITDA
25.50
EV to Capital Employed
2.67
EV to Sales
5.77
PEG Ratio
13.58
Dividend Yield
NA
ROCE (Latest)
5.64%
ROE (Latest)
6.44%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Sideways
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
178.30
210.30
-15.22%
Operating Profit (PBDIT) excl Other Income
22.70
50.90
-55.40%
Interest
10.40
0.80
1,200.00%
Exceptional Items
0.30
0.00
Consolidate Net Profit
1.60
27.20
-94.12%
Operating Profit Margin (Excl OI)
34.80%
157.70%
-12.29%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is -15.22% vs 36.03% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -94.12% vs 294.20% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
822.40
597.50
37.64%
Operating Profit (PBDIT) excl Other Income
183.00
69.40
163.69%
Interest
5.60
1.20
366.67%
Exceptional Items
-27.30
-38.50
29.09%
Consolidate Net Profit
172.20
91.80
87.58%
Operating Profit Margin (Excl OI)
140.60%
64.40%
7.62%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 37.64% vs 43.87% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 87.58% vs 398.91% in Dec 2023
About Xvivo Perfusion AB 
Xvivo Perfusion AB
Pharmaceuticals & Biotechnology
Xvivo Perfusion AB is a Sweden-based medical technology company focused on developing optimized solutions for organ, tissue and cell preservation in connection with transplantation. The Company operates in two segments: Durable goods and Non-Durable goods. The Durable goods segment comprises sale and rental income from XVIVO Perfusion System (XPS) machines. The Non-Durable goods segment implies revenue from the sale of products and services that are solutions and disposable items. The Company’s product portfolio consists of Perfadex, STEEN Solution, XPS, XPS Disposable Kit, XVIVO Lung Cannula Set, XVIVO Organ Chamber, XPS PGM Disposable Sensors and Silicone Tubing Set. The Company markets its products in Europe, Asia, Middle East, and North & South America.
Company Coordinates 
Company Details
Massans gata 10 , GOETEBORG None : 412 51
Registrar Details






